氨氯地平贝那普利胶囊由诺华研发，最早于1995年3月在美国获批上市，原研厂家的氨氯地平贝那普利 胶囊尚未在中国上市。本品用于治疗高血压，但非初治高血压。本品适用于单独服用氨氯地平或贝那普 利不能满意控制血压的患者;或同时服用氨氯地平片和贝那普利片的替代治疗。 智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到了国家药品监督管理局(简称"国家药 监局")颁发的氨氯地平贝那普利胶囊(规格：每粒含苯磺酸氨氯地平5mg(按C₂₀H₂₅ClN₂O₅计)与盐酸贝那 普利10mg)《药品注册证书》(证书编号：2025S02582)，批准该药品生产。 ...

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Levothyroxine Sodium Tablets, which will enhance the company's product line and market competitiveness [1][3]. Group 1: Drug Registration Details - The drug is named Levothyroxine Sodium Tablets, with a specification of 100μg [1]. - The drug is classified as a prescription drug and falls under the category of chemical drugs [1]. - The registration certificate was issued by the National Medical Products Administration, confirming that the drug meets the necessary registration requirements [1]. Group 2: Drug Development and Market Information - Levothyroxine Sodium Tablets were developed by Merck and were first approved for sale in France in June 1980 [2]. - The drug was approved for sale in China in July 1997 for various therapeutic uses, including treatment of non-toxic goiter and hypothyroidism [2]. - As of the announcement date, the company has invested a total of RMB 7.57 million in the research and development of this drug [2]. Group 3: Market Status of Similar Drugs - According to data from Minet, the sales revenue of Levothyroxine Sodium Tablets in China for 2024 is approximately RMB 1.14631 billion [2]. - The sales distribution includes RMB 758.17 million from urban public hospitals and county-level public hospitals, RMB 109.20 million from urban community centers and township health centers, and RMB 279.94 million from urban pharmacies and online pharmacies [2].

Core Viewpoint - The announcement indicates that Fuyuan Pharmaceutical has received the drug registration certificate for Levothyroxine Sodium Tablets, allowing the company to commence production of the drug [1] Company Summary - Fuyuan Pharmaceutical has been granted a drug registration certificate by the National Medical Products Administration for Levothyroxine Sodium Tablets, with a specification of 100μg [1]

Company Summary - Fuyuan Pharmaceutical received the drug registration certificate for Levothyroxine Sodium Tablets from the National Medical Products Administration, allowing the production of this medication [1] - For the fiscal year 2024, Fuyuan Pharmaceutical's revenue composition is as follows: 93.12% from pharmaceutical preparations, 6.46% from medical devices, 0.36% from other businesses, and 0.06% from other sources [1] - The current market capitalization of Fuyuan Pharmaceutical is 12.4 billion yuan [1] Industry Summary - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-061 北京福元医药股份有限公司 关于左甲状腺素钠片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）颁发的左甲状腺素 钠片（规格：100μg（以左甲状腺素钠计））（以下简称"该药品"） 《药品注册证书》（证书编号：2025S02491），批准该药品生产。现 将相关情况公告如下： 药品名称 药品通用名称：左甲状腺素钠片 英文名/拉丁名：Levothyroxine Sodium Tablets 剂型 片剂 注册分类 化学药品4类 规格 100μg（以左甲状腺素钠计） 药品批准文号 国药准字H20255126 药品注册标准编号 YBH19432025 处方药/非处方药 处方药 申请事项 药品注册（境内生产） 审批结论 根据《中华人民共和国药品管理法》及有关规 定，经审查，本品符合药品注册的有关要求， 一、药品注册证书主要内容 | | 批准注 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received a drug registration certificate from the National Medical Products Administration for Levothyroxine Sodium Tablets (100μg), allowing the production of this medication [1] Group 1: Product Approval - The Levothyroxine Sodium Tablets were developed by Merck and were first approved for sale in France in June 1980 [1] - The drug was approved for domestic sale in China in July 1997 by the National Medical Products Administration [1] Group 2: Indications - Levothyroxine Sodium Tablets are indicated for the treatment of non-toxic goiter (with normal thyroid function) [1] - The medication is used to prevent the recurrence of goiter after thyroidectomy [1] - It serves as a replacement therapy for hypothyroidism [1] - The drug is also an adjunct treatment for hyperthyroidism when using antithyroid medications [1] - It is indicated for suppression therapy after thyroid cancer surgery [1] - The tablets are used in thyroid suppression tests [1]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Levothyroxine Sodium Tablets, indicating approval for production [1] Group 1 - The Levothyroxine Sodium Tablets are approved in a specification of 100μg (based on Levothyroxine Sodium) [1] - The drug was developed by Merck and was first approved for marketing in France in June 1980 [1] - The company received the acceptance notice for the application on March 27, 2024, and has invested a total of RMB 7.57 million in research and development for this drug as of the announcement date (unaudited) [1]

Group 1: Company Insights - Guangdian Measurement is actively aligning with national strategies, focusing on emerging industries such as low-altitude economy and artificial intelligence, and has established a comprehensive service capability in the integrated circuit testing industry [1] - Xunjiexing has three production bases, with significant capacity expansion expected from its Xinfeng plant in October 2023 and the Zhuhai base in mid-2025, targeting growth in smart security and automotive electronics [2] - Beijing Fuyuan Pharmaceutical is projected to achieve revenue of 1.634 billion yuan and net profit of 268 million yuan in the first half of 2025, with a focus on multi-product R&D strategies to mitigate risks [3] - Gigabit has introduced innovative gameplay in its new titles, with a focus on user experience and market expansion, while maintaining a stable performance in existing games [4] - Desay SV's revenue for the first half of 2025 is expected to reach 14.644 billion yuan, with a year-on-year growth of 25.25%, driven by strong performance in smart driving and cockpit businesses [5] - Huitian New Materials has seen significant growth in its automotive business, particularly in lithium battery applications, and is expanding its product offerings in solid-state battery technology [6] - Guangwei Composite is expanding its carbon fiber applications across various sectors, with a focus on improving operational efficiency and product performance [7] - Longxin Group's energy digitalization business is projected to generate approximately 470 million yuan in revenue in the first half of 2025, with significant growth in energy internet services [8] Group 2: Market Trends and Projections - The integrated circuit testing industry is experiencing growth due to advancements in technology and increased demand for quality assurance services [1] - The smart electronics market is expanding, with companies like Xunjiexing capitalizing on the demand for high-end PCB services [2] - The pharmaceutical industry is focusing on R&D and patent strategies to enhance market competitiveness and address unmet clinical needs [3] - The gaming industry is evolving with innovative gameplay and user-centric approaches, indicating a shift in consumer preferences [4] - The automotive sector is witnessing rapid growth in smart driving technologies, reflecting a broader trend towards automation and enhanced vehicle safety [5] - The materials industry is adapting to the growing demand for electric vehicle components, particularly in the context of lithium battery technology [6] - The composite materials market is diversifying, with applications in various high-tech industries, indicating a robust growth trajectory [7] - The energy sector is increasingly integrating digital solutions to enhance efficiency and service delivery, driven by the rise of renewable energy sources [8]

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

资金流向方面，今日该股主力资金净流出1.64亿元，其中，特大单净流出9393.62万元，大单资金净流出 7017.31万元。近5日主力资金净流出2.29亿元。 8月19日公司发布的半年报数据显示，上半年公司共实现营业收入16.34亿元，同比下降1.30%，实现净 利润2.68亿元，同比下降7.83%。（数据宝） 福元医药8月20日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 沪股通专用 | 5080.40 | | | 买二 | 机构专用 | 2098.06 | | | 买三 | 国泰海通证券股份有限公司总部 | 1155.76 | | | 买四 | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1002.98 | | | 买五 | 中国国际金融股份有限公司北京建国门外大街证券营业 | 970.46 | | | | 部 | | | | 卖一 | 中银国际证券股份有限公司上海欧阳路证券营业部 | | 3969.11 | | 卖二 | 东北证券股份有限公司杭州市心北路证券营 ...